Geron Announces Grant of European Patent for Telomerase Activity Assays - 500 Beiträge pro Seite

[Greenspan2]

Thursday September 7, 7:35 am Eastern Time

Press Release

Geron Announces Grant of European Patent for
Telomerase Activity Assays

MENLO PARK, Calif.--(BUSINESS WIRE)--Sept. 7, 2000--Geron Corporation
(Nasdaq:GERN - news) announced today that the European Patent Office has granted
Geron a patent covering telomerase activity assays. The grant of this patent brings Geron`s
telomerase-related portfolio to 45 issued or allowed U.S. patents and 13 granted foreign patents. In addition, Geron has over
160 telomerase-related pending patent applications.

The patent, European Patent No. 0728207, includes 61 claims based on telomerase activity assays, including Geron`s
Telomeric Repeat Amplification Protocol (TRAP). Certain of the claims specifically cover the methods of detecting telomerase
activity in cells, including cancer cells. In addition, the patent covers kits useful for detecting telomerase activity.

``Telomerase activity is a broadly applicable and highly specific marker for cancer,`` noted Calvin Harley, Ph.D., Geron`s chief
scientific officer. ``The assays covered by this patent provide a sensitive test for telomerase activity and could be used in cancer
prognosis and diagnosis, as well as for monitoring the efficacy of therapeutic treatment regimens. There are also applications for
monitoring this enzyme during telomerase activation for the treatment of other age-related diseases.``

In collaboration with marketing partners, Geron has developed and commercialized ten research-use-only assay kits that either
detect telomerase activity or measure telomere length. In addition, under license from Geron, Roche Diagnostics GmbH is
currently conducting clinical studies of assays for the diagnosis of cancer patients.

The newly granted European patent also includes claims for screening agents which modulate telomerase activity. Since
telomerase activity appears necessary (but not sufficient) for most cancers to develop, there is much interest in the development
of telomerase inhibitors as cancer therapeutics. Geron is working in collaboration with its pharmaceutical partners, Pharmacia
and Kyowa Hakko, to identify telomerase inhibitors.

``This European patent further strengthens Geron`s intellectual property base of telomerase-related patents,`` noted David J.
Earp, Ph.D., J.D., Geron`s vice president of intellectual property. ``Geron already has a number of issued U.S. patents for
telomerase assays and cancer diagnosis based on telomerase activity. Given the potential value of this technology, a strong
international patent portfolio is important and will contribute to the successful development of diagnostic tests and therapies for
human diseases.``

Geron is a biopharmaceutical company focused on discovering, developing and commercializing therapeutic and diagnostic
products for applications in oncology and regenerative medicine, and research tools for drug discovery. Geron`s product
development programs are based upon three patented core technologies: telomerase, human pluripotent stem cells and nuclear
transfer.

This news release may contain forward-looking statements made pursuant to the ``safe harbor`` provisions of the Private
Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release
regarding product development and future applications of Geron`s technology constitute forward-looking statements that
involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential
products, our dependence on collaborative partners to perform their respective responsibilities, and the maintenance of our
intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements.
Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time
to time in Geron`s periodic reports, including the quarterly report on Form 10-Q for the quarter ended June 30, 2000.

To receive an index and copies of recent press releases, call Geron`s News On Demand toll-free fax service, 800/782-3279.
Additional information about Geron Corporation can be obtained at http://www.geron.com.

[nobes]

KurDeutsch:
Menlo-Park, Calif. -- (BUSINESS WIRE) -- Sept.. 7, 2000 -- Geron Corporation (Nasdaq:GERN - Nachrichten) verkündete heute, daß das europäische Patentamt Geron eine Patentbedeckungtelomerase-Aktivität Proben bewilligt hat. Die Bewilligung dieses Patents holt Geron`s telomerase-in Verbindung stehende Mappe zu 45 herausgegeben oder zu erlaubten US-Patenten und zu 13 bewilligten fremden Patenten. Zusätzlich hat Geron über 160 telomerase-in Verbindung stehend während Patentanfragen. Das Patent, europäisches Patent Nr. 0728207, umfaßt 61 Ansprüche, die auf telomeraseaktivität Proben, einschließlich des Protokolls Verstärkung Wiederholung Geron`s Telomeric (FALLE) basieren. Sicher der Ansprüche umfassen Sie spezifisch die Methoden des Ermittelns von telomeraseaktivität in den Zellen, einschließlich der Krebszellen. Zusätzlich bedeckt das Patent die Installationssätze, die für das Ermitteln von telomeraseaktivität nützlich sind. ``Telomerase-Aktivität ist eine breit anwendbare und in hohem Grade spezifische Markierung für Krebs, `` beachteter Calvin Harley, Ph.D., wissenschaftlicher hauptsächlichoffizier Geron`s. ``The-Proben bedeckten durch dieses Patent zur Verfügung stellen einen empfindlichen Test für telomeraseaktivität und konnten in der Krebsprognose und -diagnose, sowie für die Überwachung der Wirksamkeit der therapeutischen Behandlungregierungen verwendet werden. Es gibt auch Anwendungen für die Überwachung dieses Enzyms während der telomeraseaktivierung für die Behandlung anderen altersgebundenen diseases.`` Gemeinsam mit Marketing-Partnern hat Geron sich entwickelt und in den Handel gebrachte 10 Forschung-verwenden-nur Probe Installationssätze, denen entweder telomeraseaktivität oder -masstelomerelänge ermitteln Sie. Zusätzlich unter Lizenz von Geron, leitet Diagnose GmbH Roche aktuell klinische Studien der Proben für die Diagnose der Krebspatienten. Das eben bewilligte europäische Patent umfaßt auch Ansprüche für Siebungmittel, die telomeraseaktivität modulieren

unvollständige Übersetzung von oben

Grüsse

Nobes

[Gricko]

Ehrlich gesagt versteh´ ich immer noch nicht, was Geron Corp. nun genau macht. Vielleicht nochmal in eigenen Worten?